A registrational trial of MORAb-202
Latest Information Update: 24 Jun 2021
At a glance
- Drugs Farletuzumab ecteribulin (Primary)
- Indications Solid tumours
- Focus Registrational; Therapeutic Use
- 24 Jun 2021 New trial record
- 17 Jun 2021 According to an Eisai Co Ltd media release, the companies are planning to move into the registrational stage of development for this asset as early as next year.